Acetaminophen attenuates doxorubicin-induced cardiac fibrosis via osteopontin and GATA4 regulation: Reduction of oxidant levels

Journal of Cellular Physiology

Volumn 228, Issue 10, 2013, Pages 2006-2014

  Schunke, Kathryn J ^a,b   Coyle, Luke ^a   Merrill, Gary F ^a   Denhardt, David T ^a  

^a RUTGERS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; OSTEOPONTIN; PARACETAMOL; TRANSCRIPTION FACTOR GATA 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ACETAMINOPHEN; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; DRUG INTERACTIONS; FIBROSIS; GATA4 TRANSCRIPTION FACTOR; HEART INJURIES; MALE; MICE; MYOBLASTS, CARDIAC; MYOCYTES, CARDIAC; OSTEOPONTIN; OXIDANTS; OXIDATIVE STRESS; RATS;

ANIMALIA; MUS; RATTUS;

EID: 84879534206     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24367     Document Type: Article

References (53)

1. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M. 2004. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A 101:6975-6980.
2. Barnes JL, Gorin Y. 2011. Myofibroblast differentiation during fibrosis: Role of NAD(P)H oxidases. Kidney Int 79:944-956.
3. Charron F, Nemer M. 1999. GATA transcription factors and cardiac development. Semin Cell Dev Biol 10:85-91.
4. Charron F, Paradis P, Bronchain O, Nemer G, Nemer M. 1999. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol 19:4355-4365.
5. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. 2007. Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. Mol Interv 7:147-156.
6. Chen B, Zhong L, Roush SF, Pentassuglia L, Peng X, Samaras S, Davidson JM, Sawyer DB, Lim CC. 2012. Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads to sarcomere disarray: Implications for anthracycline cardiomyopathy. PLoS ONE 7:1-13.
7. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. 2001. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107:1055-1061.
8. Frangogiannis NG. 2012. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 92:635-688.
9. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA. 1997. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 96:3063-3071.
10. Green PS, Leeuwenburgh C. 2002. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 1588:94-101.
11. Hadzimichalis NM, Baliga SS, Golfetti R, Jaques KM, Firestein BL, Merrill GF. 2007. Acetaminophen-mediated cardioprotection via inhibition of the mitochondrial permeability transition pore-induced apoptotic pathway. Am J Physiol Heart Circ Physiol 293:H3348-H3355.
12. Hunter C, Bond J, Kuo PC, Selim MA, Levinson H. 2012. The role of osteopontin and osteopontin aptamer (OPN-R3) in fibroblast activity. J Surg Res 176:348-358.
13. 2-induced injury in vivo. Expt Biol Med 233:1315-1322.
14. Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T, Suzuki YJ. 2003. Anthracycline-induced suppression of GATA-4 transcription factor: Implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63:368-377.
15. Klingel K, Kandolf R. 2010. Osteopontin: A biomarker to predict the outcome of inflammatory heart disease. Semin Thromb Hemost 36:195-202.
16. Kobayashi S, Volden P, Timm D, Mao K, Xu X, Liang Q. 2009. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem 285:793-804.
17. Lacour S, Antonios D, Gautier JC, Pallardy M. 2009. Acetaminophen and lipopolysaccharide act in synergy for the production of pro-inflammatory cytokines in murine RAW264.7 macrophages. J Immunotoxicol 6:84-93.
18. Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, Molkentin JD. 2001. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 21:7460-7469.
19. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. 1998. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101:1468-1478.
20. McTiernan CF. 2011. Fighting doxorubicin-induced cardiotoxicity with adiponectin. Cardiovasc Res 89:262-264.
21. Merrill GF. 2002. Acetaminophen and low-flow myocardial ischemia: Efficacy and antioxidant mechanisms. Amer J Physiol 282:H1341-H1349.
22. Merrill GF, Goldberg E. 2001. Antioxidant properties of acetaminophen and cardioprotection. Basic Res Cardiol 96:423-430.
23. Merrill G, McConnell P, Vandyke K, Powell S. 2001. Coronary and myocardial effects of acetaminophen: Protection during ischemia-reperfusion. American journal of physiology 280:H2631-H2638.
24. Mori R, Shaw TJ, Martin P. 2008. Molecular mechanisms linking wound inflammation and fibrosis: Knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 205:43-51.
25. Murphy AM, Thompson WR, Peng LF, Jones L 2nd. 1997. Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4. Biochem J 322:393-401.
26. Murry CE, Giachelli CM, Schwartz SM, Vracko R. 1994. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 145:1450-1462.
27. Okamoto H, Imanaka-Yoshida K. 2012. Matricellular proteins: New molecular targets to prevent heart failure. Cardiovasc Ther 30:e198-e209.
28. Renault MA, Robbesyn F, Réant P, Douin V, Daret D, Allières C, Belloc I, Couffinhal T, Arnal JF, Klingel K, Desgranges C, Dos Santos P, Charpentier F, Gadeau AP. 2010. Osteopontin expression in cardiomyocytes induces dilated cardiomyopathy. Circ Heart Fail 3:431-439.
29. Rork TH, Van Dyke K, Spiler NM, Merrill GF. 2004. Acetaminophen in the hypoxic and reoxygenated guinea pig myocardium. Expt Biol Med 229:1154-1161.
30. Rumack BH. 2004. Acetaminophen misconceptions. Hepatology 40:10-15.
31. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. 2005. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail 7:755-762.
32. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. 2009. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154-171.
33. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, Bing OH, Colucci WS. 1999. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 33:663-670.
34. Singh M, Foster CR, Dalal S, Singh K. 2010. Osteopontin: Role in extracellular matrix deposition and myocardial remodeling post-MI.J. Mol. Cell Cardiol 48:538-543.
35. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, Barsotti A, Brunelli C. 2004. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846.
36. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C, Barsotti A. 2006. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69:736-745.
37. Stawowy P, Blaschke F, Pfautsch P, Goetze S, Lippek F, Wollert-Wulf B, Fleck E, Graf K. 2002. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail 4:139-146.
38. Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE, Piantadosi CA. 2007. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest 117:3730-3741.
39. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA. 1997. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332.
40. Swain SM, Whaley FS, Ewer MS. 2003. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879.
41. Thandavarayan RA, Watanabe K, Sari FR, Ma M, Lakshmanan AP, Giridharan VV, Gurusamy N, Nishida H, Konishi T, Zhang S, Muslin AJ, Kodama M, Aizawa Y. 2010. Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38alpha mitogen-activated protein kinase mice. Free Radical Biol Med 49:1422-1431.
42. Tripathy D, Grammas P. 2009. Acetaminophen inhibits neuronal inflammation and protects neurons from oxidative stress. J Neuroinflammation 6:6-10.
43. Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K. 2001. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circulation Res 88:1080-1087.
44. Turakhia S, Venkatakrishnan CD, Dunsmore K, Wong H, Kuppusamy P, Zweier JL, Ilangovan G. 2007. Doxorubicin-induced cardiotoxicity: Direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Amer J Physiol 293:H3111-H3121.
45. Unverferth DV, Magorien RD, Unverferth BP, Talley RL, Balcerzak SP, Baba N. 1981. Human myocardial morphologic and functional changes in the first 24hours after doxorubicin administration. Cancer Treat Rep 65:1093-1097.
46. Van Dyke K, Sacks M, Qazi N. 1998. A new screening method to detect water-soluble antioxidants: Acetaminophen (Tylenol) and other phenols react as antioxidants and destroy peroxynitrite-based luminol-dependent chemiluminescence. J Biolumin Chemilumin 13:339-348.
47. Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M. 2010. Osteopontin in cardiovascular disease: A potential therapeutic target. Cardiol Rev 18:125-131.
48. Whaley-Connell A, Sowers JR. 2012. Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep 14:360-365.
49. Yu Q, Vazquez R, Khojeini EV, Patel C, Venkataramani R, Larson DF. 2009. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Amer J Physiol 297:H76-H85.
50. Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, McDermott BJ, Grieve DJ. 2010. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. Cancer Res 70:9287-9297.
51. Zheng R, Blobel GA. 2010. GATA Transcription Factors and Cancer. Genes Cancer 1:1178-1188.
52. Zhu YZ, Chong CL, Chuah SC, Huang SH, Nai HS, Tong HT, Whiteman M, Moore PK. 2006. Cardioprotective effects of nitroparacetamol and paracetamol in acute phase of myocardial infarction in experimental rats. Am J Physiol Heart Circ Physiol 290:H517-H524.
53. Zohar R, Zhu B, Liu P, Sodek J, McCulloch CA. 2004. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase-3-independent pathway. Amer J Physiol 287:H1730-H1739.